Kornimate/medical-research-clean huggingface dataset:
gait parameters analysis in post-stroke patients and in elderly fallers

Conditions: Healthy; Thalamic Pain Syndrome; Fallers

Summary: a large proportion of falls in older people occurs when walking. most studies have recently demonstrated correlation between the variations in spatiotemporal gait parameters and fall risk in elderly and in several diseases. the investigators objective is to analyse this parameters in population with gait stability disorders (post-stroke patients and fallers) to identify the most valuable and to develop/test a conglomerate stability score.

temporal-spatial gait parameters will be recorded in subjects aged 65-80 years : 30 healthy people, 30 patients at least one year post-stroke, and 30 fallers while walking on an electronic walkway gaitrite® at self-selected speed.

Eligibility criteria:
1. for healthy subjects * aged 65 to 80 years (included) ; * patient has been informed and has signed the consent form. 2. for post-stroke patients * aged 65 to 80 years (included) ; * stroke patients who had only one cerebrovascular accident, at least one year before inclusion ; * able to walk without using assisting devices or ambulatory aids ; * no cardiovascular contraindication ; * no history of neurological diseases with influence on walking capacities (excepted stroke) ; * no history of vestibular or orthopaedic (lower limb) disorders ; * no amblyopia ; * patient has been informed and has signed the consent form. 3. for fallers * aged 65 to 80 years (included) ; * reported 2 or more falls within 6 months prior to the beginning of the study ; * able to walk without using assisting devices or ambulatory aids ; * no cardiovascular contraindication ; * no history of neurological diseases with influence on walking capacities ; * no history of vestibular or orthopaedic (lower limb) disorders ; * no amblyopia ; * patient has been informed and has signed the consent form.

Keywords: gait stability spatiotemporal parameters walking elderly people stroke fallers
improving bi-manual activities in stroke patients with application of neuro-stimulation

Conditions: Stroke; Deficit in Manual Activities

Summary: noninvasive brain stimulations (nibs) will be used in healthy volunteers and in chronic stroke patients to improve bimanual activities and motor learning. functional magnetic resonance imaging will be used to evaluate the mechanisms underlying bimanual activities and motor learning in healthy volunteers and in chronic stroke patients. a neuro-rehabilitation robot (rea2plan, axinesis, louvain-la-neuve, belgium) will be used for motor learning.

tdcs will be used in a sham-controlled, double-blind, randomized, cross-over control trial in chronic stroke patients with motor deficits. after informed consent and recruitment, patients will be randomly (computer method) allocated to real or sham tdcs, that will be applied during performance of bimanual activities and/or motor learning. a few minutes/hours/days/weeks after completing one trial's arm, the patients will enter the other trial's arm (double-blind cross-over design). baseline and follow-up outcomes about bimanual and unimanual motor tasks will be collected. for a subset of subjects, motor learning and data acquisition will be performed with a neuro-rehabilitation robot (rea2plan, axinesis, louvain-la-neuve, belgium) .

Eligibility criteria:
inclusion criteria: • stroke with at least slight deficit exclusion criteria: * epilepsy * contraindication to tdcs and/or to fmri * presence of metal in the head * inability to understand / complete behavioral tasks * chronic intake of alcohol or recreational drugs * major health condition * presence of pacemaker (for the fmri part only) * pregnancy

Keywords: bi-manual , motor skill learning , stroke , chronic patients,neuro-rehabilitative robot
testing a primary care model for the treatment of opioid dependence using long-acting injectable naltrexone (vivitrol).

Conditions: Drug Dependence

Summary: in opioid dependent patients treated with long-acting injectable naltrexone (vivitrol ®), we will compare the efficacy of a primary care model of counseling (condition 1) versus individualized cognitive-behavioral psychotherapy (condition 2) for the treatment of opioid dependence. treatment will last 12 weeks, and participants will be given 380mg of naltrexone per injection (3 injections in total; each lasting 4 weeks). primary outcomes will be 1) percent of opioid negative urines and 2) treatment compliance as measured by attendance and time in treatment. secondary outcomes are opiate craving, opiate withdrawal symptoms, perceived stress scores, severity of addiction problems, and patient satisfaction. findings will elucidate whether injectable, long-acting naltrexone would be safe and effective in a primary care setting where medication would be administered in the absence of traditional cognitive-behavioral psychotherapy and indicate whether cognitive-behavioral psychotherapy adds to treatment effects above and beyond primary care counseling. if positive, this small controlled study will provide effect size estimates for a larger trial to assess vivitrol ® in a primary care setting.


Eligibility criteria:
inclusion criteria: * male or female individuals, ages 18 and above, meeting current diagnostic and statistical manual (dsm-iv) criteria for opioid dependence. * subject has voluntarily given informed consent and signed the informed consent document. * able to read english and complete study evaluations. exclusion criteria: * regular use of benzodiazepines. * psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal, current mania); * significant underlying medical conditions such as cerebral, renal, thyroid or cardiac pathology which in the opinion of study physician would preclude patient from fully cooperating or be of potential harm during the course of the study; * abstinent from opiates for more than four weeks prior to naltrexone initiation. * medical problems that would preclude naltrexone treatment, such as laboratory evidence of significant hepato-cellular injury as evidenced by abnormal liver enzyme tests including sgot and sgpt (\> three times normal) or elevated bilirubin levels), and a history of cirrhosis. * women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by pregnancy tests during initial evaluation for naltrexone, and every two weeks during the course of the study).

Keywords: opioids, vivitrol, naltrexone, primary care
aerosolized beta-agonist isomers in asthma

Conditions: Asthma

Summary: dr. macintyre and his colleagues are studying inhaled medications in asthma. there are two new medications that have been approved by the united states food and drug administration (fda): levalbuterol and formoterol. both of these drugs are similar to standard asthma bronchodilator drugs but offer theoretical advantages in terms of fewer side effects. there are also newer devices to deliver these medications into the lungs: breath actuated nebulizers (bans) and non-static chambers (aerochamber-max) that can be used with metered dose inhalers (mdis or "puffers"). the purpose of this study is to deliver these new medications using several different devices and measuring lung function, heart rate, and sensations of breathlessness.

patients will be studied on five separate mornings. the duration of the study and frequency of the visits will be solely dependant on the subject availability. each subject will receive all 5 treatments in the same order.

Eligibility criteria:
inclusion criteria: * stable mild to moderate persistent asthma as defined by the national asthma education and prevention program * greater than 18 years of age * requiring bronchodilator therapy either routinely or on a as needed (prn)basis * stable with respect to respiratory disease and at least four weeks removed from the most recent acute exacerbation of the disease * patients may or may not be on inhaled corticosteroids exclusion criteria: * no unstable cardiovascular symptoms * no unstable angina * must be at least four weeks removed from an acute coronary syndrome

Keywords: asthma
a clinical study of mk-1045 (cn201) in people with precursor b-cell acute lymphoblastic leukemia (mk-1045-002)

Conditions: Acute Lymphoblastic Leukemia

Summary: researchers are looking for new ways to treat people with a type of blood cancer called precursor b-cell acute lymphoblastic leukemia (b-all) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. this study will have two parts. in the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, mk-1045, and to find the best dose level of mk-1045 that is tolerated and may work to treat b-all. in the second part (phase ii) researchers want to learn how well mk-1045 works to treat b-all


Eligibility criteria:
the main inclusion criteria include but are not limited to: * adult participants must be age 18 or older * pediatric participants must be at least 2 years old and less than 18 years old. * diagnosis of precursor b-cell acute lymphoblastic leukemia (b-all) and have more than 5% blasts in the bone marrow by morphological assessment * participants with ph-negative b-all with any of the following refractory/relapse criteria: * failure to achieve complete remission after initial induction therapy; * failure to achieve complete remission after salvage treatment; * relapse with first remission duration ≤12 months * second or later relapse * relapse after allogeneic hsct * participants with ph-positive b-all who have received 2 (or more) tyrosine kinase inhibitors (tkis) and meet the refractory/relapse criteria above or, those with the t315i mutation the main exclusion criteria include but are not limited to: * history of burkitt's leukemia. * received anti-cd19 therapy within 3 months prior to entering the study * received allogeneic hsct within 12 weeks prior to entering the study * received prior treatment with chimeric antigen receptor t cell (car-t) within 3 months prior to entering the study * history or presence of clinically relevant central nervous system (cns) pathology * history of clinically symptomatic metastases to the central nervous system or meninges, or other evidence of uncontrolled metastases to the cns or meninges * history of immunodeficiency, including history of any positive test result for human immunodeficiency virus (hiv) antibody. * history of serious cardiovascular and cerebrovascular disease * has active autoimmune diseases that may relapse
effects of cognitive and emotional functioning on treatment outcomes

Conditions: Eating Disorders

Summary: the investigators are interested about the degree to which individuals can persist with individualized treatment goals when their cues (external such as food, or internal such as anxiety) are high for impulsive/maladaptive behavior (e.g., purging, not eating, etc.). the investigators want to find specific high-difficulty situations in which to assess whether participants remain mindful of the big picture and are willing to work toward therapeutic goals. also, the investigators want to rate the participants degree of success (e.g., proportion of calories eaten) assessed more objectively. the theory is that working memory capacity (wmc) modulates the ability to keep longer-term goals in mind when faced by current stress/temptations. for example, the ability to control drinking when one has an implicit urge to drink is predicted by wmc. the ability to apply a novel emotional regulation skill at a time of stress is also predicted by wmc. indeed, the generic ability to pursue goals in the future (as assessed by the discounting of the value of future goals) is reliably predicted by wmc. there is also evidence that activation of brain regions associated with wmc (by direct activation of the dorsolateral prefrontal cortex via transcranial magnetic stimulation (tms), or by having a person complete a relevant cognitive task) improves delay discounting. accordingly, the investigators are proposing a study that both assesses the link between wmc and relevant the clinical measures noted above, as well as changes in these measures following activation of wm with a cognitive prime (wm task). the overall design calls for an initial wmc assessment, followed by randomization to complete 3 days of a wm prime and then 3 days of a no prime group, or vice versa. the investigators then assess the clinical outcomes noted above across the following 6 days, with a wm prime first or no prime first occurring prior to the targeted behaviors. the investigators will prime wm prior to participant's evening meal, with the wm intervention offered during the free time before this meal.


Eligibility criteria:
inclusion criteria: * residential patients * females 18 and older * able to provide informed consent for the study * sufficient command of the english language * have experience using a computer and mouse * diagnosed with an eating disorder exclusion criteria: none

Keywords: working memory adherence
screening of abdominal aortic aneurysms among male patients with tia symptoms

Conditions: Abdominal Aortic Aneurysm

Summary: the purpose of this study is to investigate the prevalence of abdominal aortic aneurysms (aaa) among male patients with transient ischemic attack (tia) symptoms. ethiology of aaa is known to be common with atherosclerotic arterial diseases (coronary artery disease, peripheral artery disease and carotid artery disease), so the hypothesis is that aaa should be more common among these tia patients, thus making screening of these patients (for aaa) more cost-efficient. study will be carried out as a prospective screening study. data will be collected in north karelia central hospital within one year. all male patients with tia symptoms will be recruited for the study and screened for aaa with ultrasound.


Eligibility criteria:
inclusion criteria: * male patient who has had symptoms of transient ischemic attack (tia) exclusion criteria: * patient's denial to participate * female gender * already diagnosed or treated abdominal aortic aneurysm
integrated client care project trial: wound care evaluation

Conditions: Wound

Summary: this study will use a randomized control trial design to compare wound care clients who receive "integrated care" versus "usual care" in community care access centres (ccac) in ontario. data will be collected by existing administrative databases and linked by the institute for clinical evaluative sciences (ices). the researchers will analyze these databases and report findings.

the researchers are interested in finding out whether the intervention ("integrated care") helps to improve patient outcomes. a randomized control trial of wound care clients in ontario ccacs will show the effects of the intervention (integrated care) versus "usual care" clients. the researchers will also examine the financial system costs associated with providing "integrated care" to clients versus "usual care". the researchers expect to answer the research question of whether there is difference in patient outcomes between "integrated care" versus "usual care clients." the researchers also would like to formulate a response for whether there will be financial system cost difference between "integrated care" and "usual care" clients. the goal of this evaluation is to help decision-makers in the ministry of health and long term care (mohltc), in the community care access centres (ccacs) and among provider organizations to improve the quality of care and patient outcomes for wound care clients, by evaluating innovations in the delivery of care.

Eligibility criteria:
inclusion criteria: * receives wound care from community care access centre provider * adults over age 18 in ontario exclusion criteria: * patients who do not receive wound care from ontario community care access centres
clinical results of odyliresin (iresine celosia) in symptomatic benign prostatic hyperplasia

Conditions: Benign Prostatic Hypertrophy With Outflow Obstruction; Benign Prostatic Hyperplasia

Summary: odyliresin (iresine celosia) is a cytochrome-flavoprotein with a powerful anti-oxydant action on cells, has a therapeutic effect on bph-related luts, reducing symptoms, prostate volume, improving the patient's quality of life and eventually limiting the number of patients who require surgery or endoscopy after medical treatment.

the aim of this phase ii open clinical trial was to determine if odyliresin, given its unique chemical structure, has a therapeutic effect on bph-related luts, so as to reduce symptoms, prostate volume, improve the patient's quality of life and eventually to limit number of patients who require surgery or endoscopy after medical treatment. to this aim, patients who seek specialist advice for luts with no previous surgical treatment for bph have been selected for treatment with odyliresin in addition to an alpha-antagonist, in order determine whether at 12 months a clinical result is obtained, if after 6 and 12 months bph symptoms are significantly improved, and a reduction of prostatic volume can be observed, thus changing the usual course of the disease. all patients with bph-related luts received both alphalitic and odyliresin treatment, clinical parameters and uroflowmetry parameters significantly improved, adenoma volume and post-void residual volume were significantly reduced at 12 month. this is the first clinical experience with iresine celosia in bph.

Eligibility criteria:
inclusion criteria: * 45 years of age or older * clinically diagnosed with mild to moderate bph * prostatic volume ≥ 30 ml determined by transrectal ultrasound * maximum flow rate (qmax) \< 15 ml/sec for a voided volume 150-500 ml exclusion criteria: * participants must not have severe bph (ipss symptom score \>21) * participants should not be currently undergoing any other form of medical therapy for bph (5-pde inhibitors, mepartricine, plant extracts such as saw palmetto, vitamin e, and quercetin). * patients must not have undergone prior transurethral resection of the prostate (turp). * post void residual (pvd) \> 200 ml * previous urological history including urethral stricture disease and/or bladder neck disease, urinary retention, bladder stone, chronic prostatitis, bladder cancer, interstitial cystitis, active upper tract stone disease causing symptoms, insulin-dependent diabetes mellitus and non-controlled non-insulin-dependent diabetes mellitus, chronic renal failure

Keywords: luts iresine celosia odyliresin medical therapy
revascularization of immature anterior necrotic teeth

Conditions: Pulp Necroses

Summary: the object of this study is to compare the effect of calcium hydroxide and di-antibiotic paste as intracanal disinfectants in the 1st visit of revascularization of necrotic immature permanent anterior teeth.

dental trauma is common in children and it is the main cause of loss of pulp vitality in immature permanent anterior teeth with prevalence rate of 11% and about of 27% of traumatized anterior teeth are left untreated. dentists face many challenges during the treatment of infected immature permanent teeth. this is mainly due to the thin dentinal walls of the root and blunderbuss apices that make these teeth susceptible to fracture during and after treatment. traditionally, calcium hydroxide apexification has been the only method for managing these cases.. however, it was found that this technique caused additional reduction in root strength due to the long-term application of calcium hydroxide which may end in fracture of the tooth. the time needed for complete apexification using calcium hydroxide was reported to be variable ranging from 5 to 20 months, with failure rate 0f 30% . therefore, this technique is no longer recommended for the treatment of such cases. a recently proposed technique for the treatment of immature necrotic permanent teeth is revascularization regenerative endodontic therapy (ret). it is a biologically based technique that allow the continuation of root development and thickening of dentinal walls. this is achieved through proper disinfection o the root canal system, creation of scaffold and perfect coronal seal. for proper disinfection of the root canal system, antibiotic paste was applied as intracanal dressing for 2-3 weeks. however, the recent recommendations by the european society of endodontology advices the use of calcium hydroxide as intracanal medication instead of intracanal antibiotics. this is because of some concerns regarding the use of antibiotics which include: cytotoxicity to stem cells needed for the revascularization process, risk of antibiotic resistance and the risk of sensitization. calcium hydroxide on the other hand is widely used as intracanal disinfectant and some studies were found supporting its use in the revascularization technique, \[9, 10\]. however, the data available is not sufficient regarding the effectiveness of calcium hydroxide in revascularization of necrotic pulp. besides, more trials are needed to evaluate the clinical effectiveness of ret in management of immature necrotic permanent teeth as the evidence of using this technique is still weak.

Eligibility criteria:
inclusion criteria: * immature anterior teeth with open apices. * necrotic teeth (regardless the cause of pulpal involvement: caries, trauma or congenital anomalies). * children free from any systemic diseases that may interfere with the normal healing process. exclusion criteria: * children allergic to antibiotics to be used in the study. * unooperative children. * laxative injuries. * compromised remaining tooth structure. * internal or external root resorption

Keywords: immature teeth, revascularization
establishment and clinical application of precise slnb system in breast cancer: a randomized, multicenter, controlled study

Conditions: Breast Cancer

Summary: the investigatorsconduct the precise sentinel lymph node biopsy using preoperative computed tomographic lymphography in breast cancer. the investigators aimed to summarize the law of lymphatic drainage of breast, and to conduct the accurate surgical treatment of breast cancer.

aim:sentinel lymph node biopsy (slnb) is the standard technique for patients with early stage breast cancer. the investigators conduct the precise sentinel lymph node biopsy using preoperative computed tomographic lymphography in breast cancer. and the investigators identify the true sentinel lymph nodes(slns) followed by lymphatic ducts during operation. the investigators aimed to identify the non-sentinel lymph node, and to investigate the relationship between upper extremity lymphatic drainage. the slnb procedure could avoid unnecessary lymph node resection and reduce treatment-related sequela. arm1： 1. participants received preoperative computed tomographic lymphography 2. participants received sentinel lymph node biopsy（slnb） 3. participants received stained non-sentinel lymph node resection during slnb 4. participants received axillary reverse mapping dissection arm2： participants receive sentinel lymph node biopsy

Eligibility criteria:
inclusion criteria: 1. histologically confirmed primary breast cancer by core needle biopsy or excisional biopsy 2. abnormal para-sentinel lymph node was found by ultrasound examination 3. ultrasound-guided fine needle aspiration cytology of these nodes were performed 4. the result of fine needle aspiration cytology was negative (no tumour cell was found) 5. participants planed to perform slnb exclusion criteria: 1. pathological diagnosed ductal carcinoma in situ by excisional biopsy 2. the result of fine needle aspiration cytology was positive 3. participants has received neo-adjuvant system therapy